Reboxetine
Reboxetine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium-dependent noradrenaline transporter.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| depression | — | D003863 | F33.9 |
| panic disorder | EFO_0004262 | D016584 | F41.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 7 | — | 1 | — | 8 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | 1 | 1 | — | 3 |
| Depression | D003863 | F33.9 | — | — | 1 | 1 | — | 2 | |
| Abdominal pain | D015746 | R10.9 | — | — | — | 1 | — | 1 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 1 | 2 | — | — | 3 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | 3 | — | — | 3 |
| Cataplexy | D002385 | — | — | 2 | — | — | 2 | ||
| Disorders of excessive somnolence | D006970 | G47.1 | — | — | 2 | — | — | 2 | |
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | 1 | 2 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Sleepiness | D000077260 | R40.0 | — | 1 | — | — | — | 1 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | — | — | 1 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stress urinary incontinence | D014550 | HP_0010992 | 1 | — | — | — | — | 1 | |
| Fecal incontinence | D005242 | R15 | 1 | — | — | — | — | 1 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 4 | 4 | ||
| Decision making | D003657 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | REBOXETINE |
| INN | reboxetine |
| Description | Reboxetine is an aromatic ether. |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccccc1OC(c1ccccc1)C1CNCCO1 |
Identifiers
| PDB | — |
| CAS-ID | 105017-38-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL14370 |
| ChEBI ID | — |
| PubChem CID | 127151 |
| DrugBank | DB00234 |
| UNII ID | 947S0YZ36I (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,123 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
289 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more